laropiprant / nicotinic acid

This medicine is now withdrawn from use in the European Union.


The marketing authorisation for Tredaptive has been withdrawn at the request of the marketing-authorisation holder.

This EPAR was last updated on 16/05/2013

Authorisation details

Product details
Agency product number
Active substance
  • laropiprant
  • nicotinic acid
International non-proprietary name (INN) or common name
  • laropiprant
  • nicotinic acid
Therapeutic area (MeSH)
Anatomical therapeutic chemical (ATC) code
Publication details
Marketing-authorisation holder
Merck Sharp Dohme Ltd.
Date of issue of marketing authorisation valid throughout the European Union
Contact address
Merck Sharp Dohme Ltd
Hertford Road
EN11 9BU
United Kingdom

Product information

10/04/2013 Tredaptive - EMEA/H/C/000889 - A20/0038

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Lipid modifying agents

Therapeutic indication

Tredaptive is indicated for the treatment of dyslipidaemia, particularly in patients with combined mixed dyslipidaemia (characterised by elevated levels of low-density-lipoprotein (LDL) cholesterol and triglycerides and low high-density-lipoprotein (HDL) cholesterol) and in patients with primary hypercholesterolaemia (heterozygous familial and non-familial).

Tredaptive should be used in patients in combination with 3-hydroxy-3-methyl-glutaryl-co-enzyme-A (HMG-CoA)-reductase inhibitors (statins), when the cholesterol-lowering effect of HMG-CoA-reductase inhibitor monotherapy is inadequate. It can be used as monotherapy only in patients in whom HMG-CoA-reductase inhibitors are considered inappropriate or not tolerated. Diet and other non-pharmacological treatments (e.g. exercise, weight reduction) should be continued during therapy with Tredaptive.

Assessment history

Changes since initial authorisation of medicine

Related content

How useful was this page?

Add your rating